- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00196417
The HIT-TRAP Trial
Randomized-Double Blind Trial to Assess the Incidence and Clinical Relevance of Heparin-Induced Thrombocytopenia (HIT) Antibodies in Trauma Patients Treated With Unfractionated or Low-Molecular Weight Heparin, the HIT-TRAP Trial
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This is a randomised, double blind trial including trauma patients with need for thrombosis prophylaxis with heparin. Patients receive either unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH).
Heparin-induced thrombocytopenia (HIT) antibodies are measured on days 1 and 10. There are daily platelet counts. On discharge an ultrasound doppler of the lower extremities is performed to rule out deep vein thrombosis (DVT).
Three months after discharge every patient is answering a questionnaire about thromboembolic complications following discharge.
The key questions of the study are whether the two heparins cause HIT-antibodies in differing frequencies, and if yes, whether these differences lead to different clinical outcomes.
Undersøgelsestype
Tilmelding
Fase
- Fase 4
Kontakter og lokationer
Studiesteder
-
-
-
Greifswald, Tyskland, 17489
- Ernst-Moritz-Arndt University, Depts. of Transfusion Medicine / Trauma surgery
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- trauma-surgical patient
- consent given
- minimum age 18
- expected inpatient period at least 7 days
- need for thrombosis prophylaxis with heparin
Exclusion Criteria:
- intolerance of one of the study drugs
- malignancy with life expectancy < 3 months
- pregnancy/lactation
- drug or alcohol abuse
- fibrinolytic therapy
- need for extracorporal circulation (e.g. cardiopulm. bypass, hemodialysis) at study entry
- participation in another clinical trial within 30 days prior to intended inclusion
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
---|
Frequency of formation of HIT-antibodies during prophylactic treatment with UFH or LMWH in trauma-surgical patients
|
Sekundære resultatmål
Resultatmål |
---|
Thromboembolic complications (TECs) during inpatient period in relation to heparin received and HIT-antibody status
|
TECs during 3 months following discharge in relation to heparin received and HIT-antibody status
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Andreas Greinacher, Prof. Dr., Ernst-Moritz-Arndt University Greifswald, Germany
Datoer for undersøgelser
Studer store datoer
Studiestart
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 001 (NavyGHB)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Heparin-induceret trombocytopeni
-
União Química Farmacêutica Nacional S/ABuranello e Rodrigues Consultoria em Desenvolvimento Farmacêutico Ltda...Suspenderet
-
União Química Farmacêutica Nacional S/ABuranello e Rodrigues Consultoria em Desenvolvimento Farmacêutico Ltda...Suspenderet
-
Methodist Health SystemAfsluttetUfraktioneret heparinForenede Stater
-
Rush University Medical CenterAfsluttetTrombocytopeni | Heparin | Elektroniske sundhedsjournalerForenede Stater
-
Bangkok Metropolitan Administration Medical College...AfsluttetHæmodialyse | Heparin | Hæmodiafiltration | Citrat reaktionThailand
-
Mitsubishi Tanabe Pharma CorporationAfsluttetHeparin-induceret trombocytopeni type IIFrankrig
-
Ottawa Hospital Research InstituteUkendtHeparin-induceret trombocytopeni (HIT)Canada
-
Imperial College LondonRoyal Brompton & Harefield NHS Foundation TrustAfsluttetKardiopulmonal bypass kirurgi | Ufraktioneret heparinDet Forenede Kongerige
-
Medical University of South CarolinaEunice Kennedy Shriver National Institute of Child Health and Human Development... og andre samarbejdspartnereAfsluttetHemiplegi | Spædbørns udvikling | Constraint Induced Movement TherapyForenede Stater
-
University Hospital, Strasbourg, FranceRekrutteringHeparin-induceret trombocytopeni (HIT)Frankrig
Kliniske forsøg med Standard heparin (UFH) versus certoparin (LMWH)
-
Hamilton Health Sciences CorporationCanadian Institutes of Health Research (CIHR); Canadian Critical Care Trials...AfsluttetKritisk syg | Dyb venetromboseCanada, Australien
-
Boston Scientific CorporationUniversity Medical Center Mainz; National PERT Consortium, Inc.RekrutteringLungeemboliForenede Stater, Frankrig, Det Forenede Kongerige, Irland, Schweiz, Tyskland, Holland, Østrig, Polen
-
The Medicines CompanyAfsluttetAkut koronarsyndromDanmark, Holland, Italien, Frankrig, Tyskland, Polen, Østrig, Tjekkiet, Slovenien
-
Beijing Chao Yang HospitalAfsluttetKarsygdomme | Trombose | Tromboemboli | LungeemboliKina